Statement of Need
Acute coronary syndrome is among the most common emergencies seen in the United States.
Treatment options for ACS are changing rapidly due to new anti-platelet agents, less than
optimal results with current agents, GP IIb/IIIa inhibitors, and a variety of different
stents. ACC/AHA guidelines change frequently in response to these rapid advances, challenging
busy physicians to keep abreast of current practice standards. Knowledge of the latest
clinical studies and best practice recommendations are critical to optimum management.
This CME activity, presented by leading experts in the management of ACS, offers practical
information through didactic material, case studies and facilitated peer-to-peer discussions.
Learning Objectives
At the conclusion of this continuing medical education activity, participants should be able to:
Effectively utilize current ACC/AHA Class I Recommendations for Antithrombotic Therapy in clinical practice
Identify and relate current standards of care and the latest clinical studies of pharmaceuticals used in ACS, to your clinical practice
Define potential avenues of anti-platelet resistance in Acute Coronary Syndrome therapy
Apply best practices in managing patients with various stent types
Target Audience
Cardiologists and other healthcare professionals who deal with acute coronary syndrome in
both acute and long-term care settings.
Accreditation Statement
Professional Education Services Group is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Physicians:
Professional Education Services Group designates this educational activity for a maximum
of 2.0 AMA PRA Category 1 Credits™ toward the AMA Physician’s Recognition
Award. Each physician should claim only those credits that he/she actually spent in the
activity. PESG activity number 07325.
Acknowledgement of Commercial support
This medical education activity is supported through an independent educational grant
from Daiichi-Sankyo, Inc. and Eli Lilly and Company.
Program Faculty
Christopher Cannon, MD, FACC
Senior Investigator, TIMI Study Group
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Cardiovascular Division
Boston, Massachusetts
Program Facilitators
Dominick Angiolillo, MD, PhD, FACC, FESC
Director, Thrombosis Research
Assistant Professor of Medicine
University of Florida College of Medicine
Shands Jacksonville
Jacksonville, Florida
LeRoy E. Rabbani, MD, FACC
Director, Cardiac Inpatient Services
Director, Cardiac Intensive Care Unit
Columbia University Medical Center
Columbia University College of Physicians and Surgeons
New York, New York
Disclosure Statement
Professional Education Services Group strives to ensure balance, independence, objectivity,
and scientific rigor in all of it educational programs. All faculty members participating
in this program have been required to disclose any real or apparent conflict(s) of interest
that may have a direct bearing on the subject matter of this program. This includes relationships
in place at the time of the meeting or in the twelve (12) months preceding the program with
pharmaceutical companies, biomedical device manufacturers, or other corporations whose
products or services are related to the subject matter of the presentation topic. The
intent of this policy is to identify openly any conflict of interest so that the listeners
may form their own judgments about the presentation with the full disclosure of the facts.
In addition, speakers are expected to openly disclose any off-label, experimental, or
investigational uses of drugs or devices in their presentations.
Christopher Cannon, MD, FACC
Consultant - Abbott, Alnylam Pharmaceuticals, Inc., AstraZeneca, Biosite Inc.,
Bristol-Myers Squibb Company, Eisai, Inc., GlaxoSmithKline, Johnson and Johnson,
Merck & Co., Inc., Pfizer, Inc., Sanofi-Aventis, Schering-Plough Corporation,
Tethys Bioscience, Vertex Pharmaceuticals Incorporated
Honorarium - BGB New York, DIME (Discovery Institute of Medical Education), I3DNL,
Medscape, NCME (Network for Continuing Medical Education), PRIME (Professional Resources
in Management Education, Inc.)
Dominick Angiolillo, MD, PhD, FACC, FESC
Consultant - Bristol-Myers Squibb Company, Sanofi-Aventis, Eli Lilly and Company, Daiichi-Sankyo, Inc.
Christopher Cannon, MD, FACC, is an Associate Professor of
Medicine at Harvard Medical School and an Associate Physician in the Cardiovascular
Division at Brigham and Women’s Hospital in Boston. He is a senior investigator of the
Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as
TACTICS-TIMI 18, PROVE IT-TIMI 22, CLARITY-TIMI 28, and MEDAL.
He earned his medical degree from Columbia University College of Physicians and Surgeons
in New York, and after completing his residency in internal medicine at Columbia
Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women’s
Hospital.
In addition to being a frequent lecturer, Dr. Cannon has published more than 500 original
articles, reviews, editorials, book chapters, and electronic publications in the field of
acute coronary syndromes. His research is published in journals including Circulation,
Journal of the American College of Cardiology (ACC), Lancet, Journal of the American
Medical Association, and the New England Journal of Medicine. He is Editor-in-Chief of
the journal Critical Pathways in Cardiology and a 35-book series Contemporary
Cardiology. He is editor or author of 6 books.
Dr. Cannon has received numerous awards including the Alfred Steiner Research Award,
Upjohn Achievement in Research Award, and Robert F. Loeb Award for Excellence in
Clinical Medicine. He is a fellow of the American Heart Association (AHA), and the ACC.
He serves as Chairman of the AHA’s Get With the Guidelines Science Subcommittee, and of
the ACC’s ACTION registry Steering Committee. He is the principal investigator of
several ongoing trials, including IMPROVE IT, which will evaluate the benefit of lowering
of LDL cholesterol well below 70 mg/dl with ezetimibe plus simvastatin as compared
simvastatin alone.
Dominick Angiolillo, MD, PhD, FACC, FESC
Dr Angiolillo is Director of Thrombosis Research and Associate Director of Cardiovascular
Research & Cardiovascular Imaging Core Laboratories at the University of Florida College
of Medicine-Jacksonville.
He graduated with full honors from The Catholic University of the Sacred Heart Medical
School of Rome, Italy. Afterwards he received his training in cardiology at the same
University Hospital under the direction of Prof. Attilio Maseri graduating with magna cum
laude. He then pursued his training in interventional cardiology at the Complutense
University of Madrid, Spain. Ultimately, he achieved his PhD in Cellular and Molecular
Cardiology with a dissertation on P2Y12 receptor antagonism. Much of his professional
career has been devoted to cardiovascular research. His research has been in both clinical
studies on drug-eluting stents, intravascular ultrasound, and intracoronary brachytherapy,
as well as in basic science studies on platelet function, inflammation and genetics of
cardiovascular disease, for which he has received a large number of international awards.
Dr Angiolillo has made major scientific contributions to many cardiovascular journals and
textbooks of cardiovascular medicine.
LeRoy E. Rabbani, MD, FACC
Dr. Rabbani is Professor of Clinical Medicine at Columbia University College of
Physicians and Surgeons and Associate Director of Clinical Research at the Center for
Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University
Medical Center. Dr. Rabbani is also Chief of Service in Cardiology; Director of Cardiac
Inpatient Services; and Director of the Cardiac Intensive Care Unit.
A prolific researcher, Dr. Rabbani has been principal investigator for a number of
national trials and has been the recipient of major grant awards, including the NIH
Physician Scientist Award. His major research interests focus on restenosis, inflammation
and atherothrombosis, and the pathogenesis and treatment of acute coronary syndromes.
Dr. Rabbani received his M.D. degree from Columbia University College of Physicians and
Surgeons and was a resident and chief resident with the Department of Medicine at Columbia
Presbyterian Medical Center. Following a visiting clinical fellowship in medicine at
Columbia, Dr. Rabbani was a clinical/research fellow in cardiology at Brigham and Women’s
Hospital in Boston, and a research fellow in medicine at Harvard Medical School.
He is a fellow of numerous professional organizations and societies, including the
Society of Cardiac Angiography and Interventions, American Heart Association, American
College of Cardiology, New York Academy of Medicine, and the American Society of Angiology.
Professional Education Services Group
405 Glenn Drive, Suite 4
Sterling, VA 20164 support@pesgce.com
